Skip to main
ATRC
ATRC logo

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure Inc. has reported an impressive EBITDA margin of 11.3%, reflecting a significant year-over-year increase of 460 basis points that surpassed market expectations. Although its gross margin experienced a slight contraction, the company's operating margin improved by 160 basis points, aligning well with positive consensus estimates. Growth drivers such as stronger sales from key products, including EPi-Sense and newer offerings like CryoSPHERE and EnCompass, suggest that AtriCure is positioned for continued strong performance and enhanced profitability.

Bears say

AtriCure Inc. is facing several challenges contributing to a negative outlook, including disappointing sales projections in key product categories such as Minimally Invasive Ablation and Appendage Management, which could result in revenue growth slowing to below 11%. Furthermore, the company is exposed to competitive pressures, particularly from Medtronic's Penditure surgical LAA closure device, which threatens its market share and may hinder future sales performance. Despite an increase in operating and adjusted EBITDA margins, a decline in gross margin, alongside the potential for weaker than anticipated profitability and ongoing market competition, raises concerns about financial stability and growth prospects.

AtriCure (ATRC) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Buy based on their latest research and market trends.

According to 10 analysts, AtriCure (ATRC) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.